DDInter1376 DDInter1081
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a
Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Lithium carbonate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Lithium carbonate may lead to a major life threatening interaction when taken with Cisapride
Lithium carbonate may lead to a major life threatening interaction when taken with Ivosidenib